FDA Inspection 1143134 — CTI Biopharma Corp
The FDA completed an inspection of CTI Biopharma Corp on May 25, 2021 in Seattle, WA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 25, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seattle, WA (United States)
Additional Details
Sponsor, Contract Research Organization